Indrani Kar, Margaret Kronz, Evelina Kolychev, Paula Silverman, Prateek Mendiratta, Benjamin K N Tomlinson, Jeremy Prunty, Melissa Copley, Seema Patel, Sara Caudill, Lisa Farah, Bryan Wesolowski, Tyler Crissinger, Colin Kendig, Eric Szymczak, Lindsey Duraj, John Dumot, Emily Acheson, Svetlana Lyamkin, Michelle King, Allyson Mocilnikar, Kevin Cunningham, Nikola Paulic, Uwe Botzki, Rachael Lerman, Robyn Strosaker, Shawn Osborne, Brett Glotzbecker
PURPOSE: This article highlights one health system's response to the market influx of biosimilars with the establishment of a process for formulary review and selection of preferred agents and support for therapeutic interchanges. SUMMARY: Through assessment of available literature, insurance payor coverage, and manufacturer-anticipated approvals of biosimilars, a strategic stance was developed to guide biosimilar order preparation, review, adoption, and implementation...
February 8, 2022: American Journal of Health-system Pharmacy: AJHP